Loading organizations...
Kythera Biopharmaceuticals is a clinical-stage firm developing novel prescription products for aesthetic medicine. Its lead product, ATX-101, is an injectable drug in Phase III development for reducing submental fat, commonly known as a double chin. This approach uses a proprietary synthetic formulation of sodium deoxycholate, a natural bile component, to precisely break down localized fat deposits.
Incorporated in Delaware in 2004, Kythera was founded by Dr. Gregory F. Miller, Dr. J. Daniel Kelly, and Dr. Robert P. Dempsy. Their core insight leveraged deoxycholate's biological mechanism for targeted fat reduction, applying biotechnology to aesthetic challenges. Keith R. Leonard, Jr. later served as President and CEO, guiding the company's growth.
The company targets the growing facial aesthetics market, positioning ATX-101 as a non-surgical treatment for an improved chin profile. Kythera's vision is to establish ATX-101 as a leading solution, developing a portfolio of first-in-class prescription products addressing unmet needs in aesthetic medicine.
Kythera Biopharmaceuticals has raised $98.0M across 4 funding rounds.
Kythera Biopharmaceuticals has raised $98.0M in total across 4 funding rounds.
Kythera Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing prescription products for the aesthetic medicine market, particularly its lead candidate ATX-101, an injectable drug in late-stage clinical trials for reducing submental fat (double chin).[1][2] The company targets physicians and patients seeking non-surgical aesthetic treatments, addressing the growing demand for minimally invasive solutions in fat reduction, hair biology, pigmentation modulation, and facial contouring.[1] As a subsidiary of Allergan plc, Kythera advanced toward commercialization before its independent operations ceased post-acquisition, reflecting strong growth momentum in the aesthetics sector driven by clinical progress and strategic partnerships.[1]
Kythera Biopharmaceuticals was incorporated in Delaware in June 2004 under the name Dermion, Inc., commencing operations in August 2005 and rebranding to KYTHERA Biopharmaceuticals, Inc. in July 2006 (formerly AESTHERx, Inc.).[1][5] Headquartered in Westlake Village, California, the company emerged from early research in aesthetic dermatology, quickly advancing ATX-101 into late-stage development.[1][5] Pivotal moments included securing collaboration agreements with Bayer Consumer Care AG and its affiliate Intendis GmbH for international development and commercialization of ATX-101 outside the US and Canada, alongside its eventual acquisition by Allergan plc, integrating it into a major pharma ecosystem.[1]
Kythera rode the early 2010s wave of aesthetic medicine innovation, capitalizing on rising demand for non-invasive cosmetic procedures amid aging populations and social media-driven appearance standards.[1][2] Timing aligned with biotech's shift toward targeted injectables, outpacing surgical options in safety and recovery, bolstered by favorable regulatory paths for aesthetics.[1] Market forces like expanding medical spa networks and premium pricing for treatments favored Kythera, influencing the ecosystem by validating submental fat reduction as a blockbuster category—paving the way for Allergan's Kybella (ATX-101's commercialized form) and inspiring competitors in minimally invasive aesthetics.[1]
Post-acquisition by Allergan, Kythera's legacy endures through Kybella's established market success, with future shaped by ongoing aesthetics trends like combination therapies and personalized treatments. Evolving biotech M&A dynamics will amplify such integrations, potentially expanding ATX-101 analogs into new indications amid sustained demand for non-surgical enhancements. This trajectory underscores Kythera's foundational role in transforming aesthetic medicine from niche to mainstream.
Kythera Biopharmaceuticals has raised $98.0M in total across 4 funding rounds.
Kythera Biopharmaceuticals's investors include ARCH Venture Partners, Venrock, Altitude Life Science Ventures, BBT Capital Management/Apothecary Capital, Foley Ventures, Invus Financial Advisors, Jafco Ventures, Latham & Watkins, Partner Fund Management, Prospect Venture Partners, Versant Ventures.
Kythera Biopharmaceuticals has raised $98.0M across 4 funding rounds. Most recently, it raised $37.0M Series D in September 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2011 | $37.0M Series D | ARCH Venture Partners, Venrock, Altitude Life Science Ventures, BBT Capital Management/Apothecary Capital, Foley Ventures, Invus Financial Advisors, Jafco Ventures, Latham & Watkins, Partner Fund Management, Prospect Venture Partners, Versant Ventures | |
| May 1, 2008 | $30.0M Series C | ARCH Venture Partners, Venrock | |
| Jul 1, 2006 | $30.0M Series B | ARCH Venture Partners, Venrock | |
| Sep 1, 2005 | $1.0M Seed | Venrock |